Angiogenesis in Colorectal Cancer Antibodies

被引：9

作者：

Chan, Emily ^{[1
]}

机构：

[1] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, 691 Preston Bldg, Nashville, TN 37232 USA

来源：

CANCER JOURNAL | 2016年 / 22卷 / 03期

关键词：

Antiangiogenesis; colon cancer; IV treatments; vascular endothelial growth factor (VEGF); RANDOMIZED PHASE-3 TRIAL; BEVACIZUMAB; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; RAMUCIRUMAB; COMBINATION; AFLIBERCEPT; PROGRESSION; IRINOTECAN;

D O I：

10.1097/PPO.0000000000000200

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis is critical to tumor cell growth. Vascular endothelial growth factor and its receptors play key roles in this pathway and are targets for cancer drug therapy. Blockade of the angiogenesis pathway has shown efficacy and led to improvements in survival in several tumor types. This chapter focuses on the intraveneous antiangiogenic agents approved in metastatic colorectal cancer and their role in the treatment of this disease.

引用

页码：179 / 181

页数：3

共 13 条

[1] Bevacizumab in Stage II-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Petrelli, Nicholas J. ;

Lopa, Samia H. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (03) :359-364

[2] Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].

Bennouna, Jaafar ;

Sastre, Javier ;

Arnold, Dirk ;

Osterlund, Pia ;

Greil, Richard ;

Van Cutsem, Eric ;

von Moos, Roger ;

Maria Vieitez, Jose ;

Bouche, Olivier ;

Borg, Christophe ;

Steffens, Claus-Christoph ;

Alonso-Orduna, Vicente ;

Schlichting, Christoph ;

Reyes-Rivera, Irmarie ;

Bendahmane, Belguendouz ;

Andre, Thierry ;

Kubicka, Stefan .

LANCET ONCOLOGY, 2013, 14 (01) :29-37

[3] Aflibercept [J].

Ciombor, Kristen K. ;

Berlin, Jordan ;

Chan, Emily .

CLINICAL CANCER RESEARCH, 2013, 19 (08) :1920-1925

[4] Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial [J].

Cunningham, David ;

Lang, Istvan ;

Marcuello, Eugenio ;

Lorusso, Vito ;

Ocvirk, Janja ;

Shin, Dong Bok ;

Jonker, Derek ;

Osborne, Stuart ;

Andre, Niko ;

Waterkamp, Daniel ;

Saunders, Mark P. .

LANCET ONCOLOGY, 2013, 14 (11) :1077-1085

[5] Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial [J].

de Gramont, Aimery ;

Van Cutsem, Eric ;

Schmoll, Hans-Joachim ;

Tabernero, Josep ;

Clarke, Stephen ;

Moore, Malcolm J. ;

Cunningham, David ;

Cartwright, Thomas H. ;

Hecht, J. Randolph ;

Rivera, Fernando ;

Im, Seock-Ah ;

Bodoky, Gyoergy ;

Salazar, Ramon ;

Maindrault-Goebel, Frederique ;

Shacham-Shmueli, Einat ;

Bajetta, Emilio ;

Makrutzki, Martina ;

Shang, Aijing ;

Andre, Thierry ;

Hoff, Paulo M. .

LANCET ONCOLOGY, 2012, 13 (12) :1225-1233

[6]

Ellis LM, 2006, SEMIN ONCOL, V33, pS1, DOI 10.1053/j.seminoncol.2006.08.002

[7] Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].

Giantonio, Bruce J. ;

Catalano, Paul J. ;

Meropol, Neal J. ;

O'Dwyer, Peter J. ;

Mitchell, Edith P. ;

Alberts, Steven R. ;

Schwartz, Michael A. ;

Benson, Al B., III .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544

[8] Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer? [J].

Goldstein, Daniel A. ;

El-Rayes, Bassel F. .

ONCOLOGIST, 2015, 20 (09) :981-982

[9] Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study [J].

Grothey, Axel ;

Flick, E. Dawn ;

Cohn, Allen L. ;

Bekaii-Saab, Tanios S. ;

Bendell, Johanna C. ;

Kozloff, Mark ;

Roach, Nancy ;

Mun, Yong ;

Fish, Susan ;

Hurwitz, Herbert I. .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (07) :726-734

[10] Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) [J].

Grothey, Axel ;

Sugrue, Mary M. ;

Purdie, David M. ;

Dong, Wei ;

Sargent, Daniel ;

Hedrick, Eric ;

Kozloff, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (33) :5326-5334

← 1 2 →